Back to News
Market Impact: 0.2
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
Source: GlobeNewswire
Healthcare & BiotechCompany FundamentalsCredit & Bond MarketsCorporate Guidance & Outlook
The company completed repayment of its existing loan facility, which it says strengthens financial flexibility and access to funding for corporate and commercial activities. It expects to complete enrollment in the Phase 3 4WARD trial by year-end 2026 and report topline data in H1 2028.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- French yields are near levels not seen since 2002. Why that could give U.S. Treasurys a boost
- Rising fuel costs slashed Delta’s profit outlook despite strong demand
- ‘I drive a Tesla’: After Elon Musk said he’d lose his job, Delta CEO Ed Bastian says there’s ‘no tit for tat’ as airline unveils earnings miss
- Why is the Chinese stock market missing the AI rally
- OpenAI's revenue scare, Delta earnings, what investors think of a Starbucks-Chipotle deal and more in Morning Squawk